SCHEMBL13774624

SCHEMBL13774624

O=C(CS(=O)(=O)c1ccccc1)c1ccc(-c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 10/20 0.71
▸ RECQL P46063 3/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ ACLY P53396 1/20 0.51
▸ PTPN1 P18031 1/20 0.50
▸ MMP2 P08253 1/20 0.48
▸ MMP7 P09237 1/20 0.48
▸ MMP14 P50281 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ KAT6A Q92794 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28547256 0.85 HSD11B1 (0.72) HSD11B1RECQLNPC1ALDH1A1RAB9A
SCHEMBL12577229 0.84 HSD11B1 (1.00) HSD11B1RECQLNPC1ALDH1A1RAB9A
SCHEMBL16660516 0.84 HSD11B1 (0.73) HSD11B1RECQLNPC1ALDH1A1RAB9A
SCHEMBL28395917 0.83 HSD11B1 (0.81) HSD11B1RECQLNPC1ALDH1A1RAB9A
SCHEMBL28547258 0.78 HSD11B1 (0.88) HSD11B1RECQLNPC1ALDH1A1RAB9A
SCHEMBL28392708 0.78 RECQL (0.73) HSD11B1RECQLNPC1ALDH1A1RAB9A
SCHEMBL13774627 0.77 PTPN1 (0.63) RECQLALDH1A1PTPN1MEN1KMT2A
SCHEMBL23877960 0.77 HSD11B1 (0.43) HSD11B1RAB9AACLYPTPN1KMT2A
SCHEMBL29784281 0.76 RXRA (0.72) NPC1ALDH1A1RAB9APTPN1MEN1
SCHEMBL2344585 0.76 RXRA (0.72) NPC1ALDH1A1RAB9APTPN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090179638-A1 ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS AEGERA THERAPEUTICS INC. (CA) 2009-07-16 — — US disclosed
US-20090179638-A1 ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS AEGERA THERAPEUTICS INC. (CA) 2009-07-16 — — US disclosed
WO-2007087716-A1 ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS AEGERA THERAPEUTICS INC. (CA) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090179638-A1 ASSAY FOR IDENTIFYING INHIBITORS OF NEURONAL APOPTOTIC PATHWAYS HSPBP1, HSP90AB1, HSP90AB2P HSD11B1 3069/4885RECQL 2782/4885NPC1 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback